Safety Profile of Paroxetine 7.5 mg in Women With Moderate-to-Severe Vasomotor Symptoms

被引：0
|
作者：
Simon, James A. [1 ]
Portman, David J. [1 ]
Kazempour, Kazem [1 ]
Mekonnen, Hana [1 ]
Bhaskar, Sailaja [1 ]
Lippman, Joel [1 ]
机构：
[1] George Washington Univ, Sch Med, Womens Hlth & Res Consultants, Washington, DC USA
来源：
OBSTETRICS AND GYNECOLOGY | 2014年 / 123卷
关键词：
D O I：
10.1097/01.AOG.0000447102.46167.7b
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：132S / 133S
页数：2
相关论文
共 50 条
  • [1] Paroxetine 7.5 mg to Treat Moderate to Severe Vasomotor Symptoms Associated With Menopause: Safety Profile From 3 Multicenter, Double-blind, Randomized, Controlled Trials
    Portman, David J.
    Simon, James A.
    Kazempour, Kazem
    Bhaskar, Sailaja
    Mekonnen, Hana
    Lippman, Joel
    [J]. JOURNAL OF WOMENS HEALTH, 2014, 23 (04) : 10 - 10
  • [2] Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause
    Santoro, Nanette
    Johnson, Kimball
    Nappi, Rossella E.
    Neal-Perry, Genevieve
    Shapiro, Marla
    Stute, Petra
    Thurston, Rebecca C.
    Wolfman, Wendy
    English, Marci
    Franklin, Catherine
    Lee, Misun
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 154 - 155
  • [3] Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
    Pinkerton, JoAnn V.
    Joffe, Hadine
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (01): : 50 - 58
  • [4] Efficacy of Paroxetine (7.5 mg) in the treatment of menopause-associated vasomotor symptoms
    Belardo, Maria A.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (12): : 1459 - 1459
  • [5] Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause
    Yu, Qi
    Chae, Hee-Dong
    Hsiao, Sheng-Mou
    Xie, Jipan
    Blogg, Martin
    Sumarsono, Budiwan
    Kim, Soyoung
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (05): : 553 - 563
  • [6] Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials
    Simon, James A.
    Portman, David J.
    Kaunitz, Andrew M.
    Mekonnen, Hana
    Kazempour, Kazem
    Bhaskar, Sailaja
    Lippman, Joel
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (10): : 1027 - 1035
  • [7] Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
    Simon, James A.
    [J]. WOMENS HEALTH, 2007, 3 (01) : 29 - 37
  • [8] Paroxetine 7.5 mg Provided a Rapid and Durable Reduction in Vasomotor Symptoms Associated With Menopause Following Treatment Initiation
    Portman, David
    Pinkerton, JoAnn V.
    Bhaskar, Sailaja
    Lippman, Joel
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (12): : 1333 - 1333
  • [9] Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause
    Lederman, Samuel
    Shapiro, Marla
    Stute, Petra
    Lee, Misun
    Wang, Xuegong
    Neal-Perry, Genevieve
    [J]. OBSTETRICS AND GYNECOLOGY, 2022, 139 : 39S - 39S
  • [10] Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
    Mirkin, Sebastian
    Komm, Barry
    Pickar, James H.
    [J]. WOMENS HEALTH, 2014, 10 (02) : 135 - 146
12345